FUNDAMENTALS · Fundamentals · TW Healthcare

TaiDoc Technology (4736) Fundamentals 2026 — P/E 7.1x, Revenue Analysis | SniperIQ

TaiDoc Technology (4736) is a TW-listed Healthcare company in Medical - Devices with a market capitalization of NT

2.4B, trading at NT
30.50 on the TAI. This SniperIQ fundamentals page covers TaiDoc Technology's valuation (P/E 7.1x, P/B 1.3x), profitability (net margin 40.5%), revenue (NT$4.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
2.4B
P/E (TTM)7.1x
Net Margin40.5%
Revenue (FY25)NT$4.2B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is TaiDoc Technology's market cap?

TaiDoc Technology (4736) has a market capitalization of approximately NT

2.4B, trading at NT
30.50 on the TAI. Market cap moves with the live share price.

What is TaiDoc Technology's P/E ratio?

TaiDoc Technology's trailing twelve-month P/E ratio is 7.1x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is TaiDoc Technology?

TaiDoc Technology runs a net profit margin of 40.5%, a gross margin of 46.3%, and an operating margin of 23.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does TaiDoc Technology generate?

TaiDoc Technology reported revenue of NT$4.2B for fiscal year 2025, with net income of NT

.4B and earnings per share (EPS) of 15.12. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does TaiDoc Technology pay a dividend?

TaiDoc Technology offers a trailing dividend yield of about 7.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is TaiDoc Technology financially healthy?

TaiDoc Technology carries a debt-to-equity ratio of 0.12x and a current ratio of 2.73x, with a market beta of 0.27. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is TaiDoc Technology a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For TaiDoc Technology (4736) the key facts are: market cap NT

2.4B, P/E 7.1x, revenue NT$4.2B, 52-week range 116-145. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track TaiDoc Technology's full fundamentals live

Get TaiDoc Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Tibet Rhodiola Pharmaceutical Holding (600211) fundamentals · Qingdao Baheal Medical (301015) fundamentals · Penumbra (PEN) fundamentals · Revvity (RVTY) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons